The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.
The firm aims to offer a clinical service next year for predicting immunotherapy response and adverse immune reactions.
The companies plan to commercialize MIODx's immune sequencing technology for diagnostic purposes.
The companies are planning to develop individual disease diagnostics, and then a universal diagnostic from a single blood test.
Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.
The researchers found disease-related signatures in the immune repertoire of affected patients as well as changes associated with treatment.
Enpicom will initially offer separate solutions on its ImmunoGenomiX platform for research and clinical applications in oncology but seeks to expand into other disease areas.
Adaptive will work with NCI's Cancer Therapy Evaluation Program to use its ImmunoSeq platform for biomarker discovery in clinical trials.
The company recently raised $8 million and is looking to partner with other firms interested in antigen discovery and diagnostic development.
The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
The New York City Police Department will be removing DNA profiles from a local database if they are from people who were never convicted of a crime, the New York Times reports.
Science reports that accusations of sexual assault against a microbiome researcher has also led to questions about his academic certifications.
Wired reports that researchers are analyzing the DNA fish leave behind in water to study their populations.
In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.